首页 > 最新文献

Pathophysiology最新文献

英文 中文
Knockdown of Rab9 Recovers Defective Morphological Differentiation Induced by Chemical ER Stress Inducer or PMD-Associated PLP1 Mutant Protein in FBD-102b Cells. 敲除 Rab9 可恢复 FBD-102b 细胞中由化学性 ER 压力诱导剂或与 PMD 相关的 PLP1 突变蛋白诱导的缺陷形态分化。
IF 2.7 Q2 PATHOLOGY Pub Date : 2024-08-26 DOI: 10.3390/pathophysiology31030032
Nana Fukushima, Yuki Miyamoto, Junji Yamauchi

Small GTP-binding proteins of the Rab family regulate intracellular vesicle trafficking across many aspects of the transport system. Among these, Rab9 is recognized for its role in controlling the transport system not only around the trans-Golgi network but also around the late endosome. However, the specific functions across different cell types and tissues remain unclear. Here, for the first time, we report that Rab9 negatively regulates morphological changes in the FBD-102b cell line, an oligodendroglial precursor cell line undergoing morphological differentiation. The knockdown of Rab9 led to an increase in cell shape alterations characterized by widespread membrane extensions. These changes were accompanied by increased expression levels of oligodendroglial cell differentiation and myelination marker proteins. Notably, the knockdown of Rab9 was capable of recovering defective cell morphological changes induced by tunicamycin, an inducer of endoplasmic reticulum (ER) stress, which is one of the major causes of oligodendroglial cell diseases such as Pelizaeus-Merzbacher disease (PMD, currently known as hypomyelinating leukodystrophy type 1 [HLD1]). In addition, Rab9 knockdown recovered levels of ER stress marker proteins and differentiation markers. Similar results were obtained in the cases of dithiothreitol (DTT), another chemical ER stress inducer, as well as HLD1-associated proteolipid protein 1 (PLP1) mutant protein. These results indicate a unique role for Rab9 in oligodendroglial cell morphological changes, suggesting its potential as a therapeutic target for mitigating diseases such as HLD1 at the molecular and cellular levels.

Rab 家族的小 GTP 结合蛋白在运输系统的许多方面调节细胞内囊泡的运输。其中,Rab9 因其不仅控制跨高尔基体网络周围的运输系统,还控制晚期内质体周围的运输系统而得到认可。然而,不同细胞类型和组织的具体功能仍不清楚。在这里,我们首次报道了 Rab9 负向调控正在进行形态分化的少突胶质细胞前体细胞系 FBD-102b 的形态变化。Rab9被敲除后,以广泛的膜延伸为特征的细胞形态改变增加。伴随这些变化的是少突胶质细胞分化和髓鞘化标志蛋白表达水平的增加。值得注意的是,Rab9的敲除能够恢复由内质网(ER)应激诱导剂妥卡霉素(tunicamycin)诱导的细胞形态学缺陷变化,而ER应激是导致少突胶质细胞疾病(如佩里泽斯-默茨巴赫病(PMD,目前称为髓鞘功能减退性白质营养不良症1型[HLD1])的主要原因之一。此外,Rab9基因敲除还能恢复ER应激标志蛋白和分化标志物的水平。在使用另一种化学ER应激诱导剂二硫苏糖醇(DTT)以及HLD1相关蛋白脂质蛋白1(PLP1)突变体蛋白的情况下,也得到了类似的结果。这些结果表明了 Rab9 在少突胶质细胞形态变化中的独特作用,表明它有可能成为在分子和细胞水平上缓解 HLD1 等疾病的治疗靶点。
{"title":"Knockdown of Rab9 Recovers Defective Morphological Differentiation Induced by Chemical ER Stress Inducer or PMD-Associated PLP1 Mutant Protein in FBD-102b Cells.","authors":"Nana Fukushima, Yuki Miyamoto, Junji Yamauchi","doi":"10.3390/pathophysiology31030032","DOIUrl":"10.3390/pathophysiology31030032","url":null,"abstract":"<p><p>Small GTP-binding proteins of the Rab family regulate intracellular vesicle trafficking across many aspects of the transport system. Among these, Rab9 is recognized for its role in controlling the transport system not only around the trans-Golgi network but also around the late endosome. However, the specific functions across different cell types and tissues remain unclear. Here, for the first time, we report that Rab9 negatively regulates morphological changes in the FBD-102b cell line, an oligodendroglial precursor cell line undergoing morphological differentiation. The knockdown of Rab9 led to an increase in cell shape alterations characterized by widespread membrane extensions. These changes were accompanied by increased expression levels of oligodendroglial cell differentiation and myelination marker proteins. Notably, the knockdown of Rab9 was capable of recovering defective cell morphological changes induced by tunicamycin, an inducer of endoplasmic reticulum (ER) stress, which is one of the major causes of oligodendroglial cell diseases such as Pelizaeus-Merzbacher disease (PMD, currently known as hypomyelinating leukodystrophy type 1 [HLD1]). In addition, Rab9 knockdown recovered levels of ER stress marker proteins and differentiation markers. Similar results were obtained in the cases of dithiothreitol (DTT), another chemical ER stress inducer, as well as HLD1-associated proteolipid protein 1 (PLP1) mutant protein. These results indicate a unique role for Rab9 in oligodendroglial cell morphological changes, suggesting its potential as a therapeutic target for mitigating diseases such as HLD1 at the molecular and cellular levels.</p>","PeriodicalId":19852,"journal":{"name":"Pathophysiology","volume":"31 3","pages":"420-435"},"PeriodicalIF":2.7,"publicationDate":"2024-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11417737/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142292986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sepia pharaonis Ink Mitigates Dehydroepiandrosterone-Induced Insulin Resistance in Mouse Model of Polycystic Ovarian Syndrome. 蚕墨可减轻多囊卵巢综合征小鼠模型中脱氢表雄酮诱导的胰岛素抵抗。
IF 2.7 Q2 PATHOLOGY Pub Date : 2024-08-15 DOI: 10.3390/pathophysiology31030031
Prathyusha Yamarthi, Rama Satyasri Kotipalli, Samatasai Patnaik, Kv Veena, Muralidharan Kathirvel, Rajkumar Vutukuri, Manjula Bhanoori

The present study aims to evaluate the effect of Sepia pharaonis ink on insulin resistance in PCOS-induced mice. Treatment with sepia ink in dehydroepiandrosterone (DHEA)-induced PCOS mice at various doses of 50 mg/kg, 100 mg/kg, and 200 mg/kg body weight mitigated the insulin resistance in the study groups with decreased concentration of testosterone and increased concentrations of estrogen and progesterone compared to the PCOS group tested by ELISA. The histopathological analysis and restoration of glucose analysis showed a significant reduction in treatment groups. Reduced expression of insulin resistance genes like androgen receptor (AR), insulin receptor substrate 1 (IRS-1), and insulin-like growth factor1 (IGF-1) by qRT-PCR indicate a positive impact of sepia ink in alleviating the symptoms associated with PCOS. Taken together, the results of this study indicate sepia ink as a promising therapeutic intervention and a possible drug target for insulin resistance in diabetes and gynecological disorders like PCOS.

本研究旨在评估蚕墨对多囊卵巢综合征诱导小鼠胰岛素抵抗的影响。用不同剂量(50 毫克/千克、100 毫克/千克和 200 毫克/千克体重)的海茴香墨水治疗脱氢表雄酮(DHEA)诱导的多囊卵巢综合征小鼠,缓解了研究组的胰岛素抵抗,与 ELISA 检测的多囊卵巢综合征组相比,睾酮浓度降低,雌激素和孕酮浓度升高。组织病理学分析和血糖恢复分析表明,治疗组的胰岛素抵抗显著降低。通过 qRT-PCR,雄激素受体(AR)、胰岛素受体底物 1(IRS-1)和胰岛素样生长因子 1(IGF-1)等胰岛素抵抗基因的表达量减少,这表明霞石油墨对缓解多囊卵巢综合症相关症状有积极影响。综上所述,本研究结果表明,霞石墨水是一种很有前景的治疗干预措施,也是治疗糖尿病和多囊卵巢综合征等妇科疾病中胰岛素抵抗的可能药物靶点。
{"title":"<i>Sepia pharaonis</i> Ink Mitigates Dehydroepiandrosterone-Induced Insulin Resistance in Mouse Model of Polycystic Ovarian Syndrome.","authors":"Prathyusha Yamarthi, Rama Satyasri Kotipalli, Samatasai Patnaik, Kv Veena, Muralidharan Kathirvel, Rajkumar Vutukuri, Manjula Bhanoori","doi":"10.3390/pathophysiology31030031","DOIUrl":"10.3390/pathophysiology31030031","url":null,"abstract":"<p><p>The present study aims to evaluate the effect of <i>Sepia pharaonis</i> ink on insulin resistance in PCOS-induced mice. Treatment with sepia ink in dehydroepiandrosterone (DHEA)-induced PCOS mice at various doses of 50 mg/kg, 100 mg/kg, and 200 mg/kg body weight mitigated the insulin resistance in the study groups with decreased concentration of testosterone and increased concentrations of estrogen and progesterone compared to the PCOS group tested by ELISA. The histopathological analysis and restoration of glucose analysis showed a significant reduction in treatment groups. Reduced expression of insulin resistance genes like androgen receptor (AR), insulin receptor substrate 1 (IRS-1), and insulin-like growth factor1 (IGF-1) by qRT-PCR indicate a positive impact of sepia ink in alleviating the symptoms associated with PCOS. Taken together, the results of this study indicate sepia ink as a promising therapeutic intervention and a possible drug target for insulin resistance in diabetes and gynecological disorders like PCOS.</p>","PeriodicalId":19852,"journal":{"name":"Pathophysiology","volume":"31 3","pages":"408-419"},"PeriodicalIF":2.7,"publicationDate":"2024-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11348200/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142073517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
STABILITY (Symptomatic Review during Biologic Therapy) of Inflammatory Bowel Disease Patients Receiving Infusion Therapy Improves Clinical Outcomes. 接受输液治疗的炎症性肠病患者的 STABILITY(生物疗法期间症状回顾)可改善临床疗效。
IF 2.7 Q2 PATHOLOGY Pub Date : 2024-08-12 DOI: 10.3390/pathophysiology31030030
Kelli Morgan, James Morris, Qiang Cai, Phillip Kilgore, Urska Cvek, Marjan Trutschl, Katelynn T Lofton, Meher Sindhoora Mavuram, Prerana Ramesh, Nhi Dao, Ahmed Alhaque, Jonathan Steven Alexander
<p><p>Several studies have correlate improved patient outcomes with increased physician-patient contacts, particularly in chronic diseases. Extending this approach to inflammatory bowel disease (IBD) care presents a promising means of improving outcomes. At LSU Health Shreveport (LSUHS), a new approach called "STABILITY" (Symptomatic Review during Biologic Therapy) was implemented during infusion therapy visits for IBD patients. These brief 15 min physician-patient interviews aimed to discuss the patients' current IBD-related symptoms and evaluate the need for any changes in their treatment plan. Our goal was to remove a care gap and prevent intensifying symptoms created by missed appointments and loss of contact. To analyze the effectiveness of the STABILITY approach, a retrospective chart review was conducted on 111 IBD patients (18 with ulcerative colitis, 93 with Crohn's disease) seen at LSUHS between 2011 and 2022. Since March 2019, STABILITY has been mandatory for all infusion therapy visits. The data collected included patients' demographics, lab levels for biomarkers (fecal calprotectin, C-reactive protein, and erythrocyte sedimentation rates), hospitalizations, medication changes, and diagnosis dates before and after the implementation of STABILITY. Additionally, voluntary, anonymous infusion patient satisfaction surveys post-STABILITY were used to gather patient responses. In males with IBD, disease severity and hospitalizations were reduced significantly (<i>p</i> = 0.004 and 0.0234, respectively). In females with IBD, disease severity and hospitalizations were also reduced significantly (<i>p</i> = 0.0001 and 0.0072, respectively). In patients with UC and CD, there were significant improvements in disease severity (<i>p</i> = 0.043 and <i>p</i> = 0.0001, respectively), and CD hospitalizations were also improved (<i>p</i> = 0.0013). In males and females with UC, disease severity was marginally and significantly reduced (<i>p</i> = 0.0781 and <i>p</i> = 0.0379, respectively). In males and females with CD, disease severity was significantly reduced (<i>p</i> = 0.0161 and 0.0003, respectively), and CD male and female hospitalizations were also reduced significantly (<i>p</i> = 0.0436 and 0.013). Analyzing of survey responses, we found that the most patients reported improved IBD symptoms (56%), gained understanding of their condition (84%) and were in favor of continuing STABILITY consultations during infusion therapy (93%). To further investigate the impact of STABILITY, we conducted a comparative analysis between IBD patients undergoing STABILITY infusion therapy and LSUHS patients solely on self-injectable biologics. Our paired data analysis showed significant improvements in disease severity in female IBD patients (1.69 ± 0.13 vs. 1.41 ± 0.12, <i>p</i> = 0.0001) and male IBD patients (1.58 ± 0.16 vs. 1.2 ± 0.135, <i>p</i> = 0.004), in UC patients (1.833 ± 0.4.2 vs. 1.444, <i>p</i> = 0.043), in all CD patients (1.59 ± 0.11 vs. 1.29 ± 0
多项研究表明,患者治疗效果的改善与医患接触的增加有关,尤其是在慢性疾病方面。将这种方法推广到炎症性肠病(IBD)的治疗中是一种很有前景的改善治疗效果的方法。在路易斯安那州立大学什里夫波特分校(LSUHS),一种名为 "STABILITY"(生物治疗过程中的症状回顾)的新方法在 IBD 患者的输液治疗就诊过程中实施。这些简短的 15 分钟医患访谈旨在讨论患者当前的 IBD 相关症状,并评估是否需要更改治疗方案。我们的目标是消除护理空白,防止因错过预约和失去联系而导致症状加重。为了分析 STABILITY 方法的有效性,我们对 2011 年至 2022 年期间在路易斯安那州立大学健康学院就诊的 111 名 IBD 患者(18 名溃疡性结肠炎患者,93 名克罗恩病患者)进行了回顾性病历审查。自2019年3月起,STABILITY成为所有输液治疗就诊的强制要求。收集的数据包括实施 STABILITY 前后患者的人口统计学特征、生物标志物(粪便热保护蛋白、C 反应蛋白和红细胞沉降率)的实验室水平、住院情况、药物更换情况和诊断日期。此外,还采用自愿、匿名的输液患者满意度调查来收集患者对 STABILITY 实施后的反应。在 IBD 男性患者中,疾病严重程度和住院次数明显减少(p = 0.004 和 0.0234)。女性 IBD 患者的疾病严重程度和住院次数也明显减少(p = 0.0001 和 0.0072)。在 UC 和 CD 患者中,疾病严重程度有明显改善(分别为 p = 0.043 和 p = 0.0001),CD 住院治疗情况也有所改善(p = 0.0013)。在男性和女性 UC 患者中,疾病严重程度略有显著降低(分别为 p = 0.0781 和 p = 0.0379)。在男性和女性 CD 患者中,疾病严重程度显著降低(分别为 p = 0.0161 和 0.0003),男性和女性 CD 患者的住院率也显著降低(分别为 p = 0.0436 和 0.013)。通过分析调查反馈,我们发现大多数患者表示 IBD 症状得到了改善(56%),对病情有了更多了解(84%),并赞成在输液治疗期间继续接受 STABILITY 咨询(93%)。为了进一步研究 STABILITY 的影响,我们对接受 STABILITY 输液治疗的 IBD 患者和仅接受自我注射生物制剂治疗的 LSUHS 患者进行了对比分析。我们的配对数据分析显示,女性 IBD 患者(1.69 ± 0.13 vs. 1.41 ± 0.12,p = 0.0001)和男性 IBD 患者(1.58 ± 0.16 vs. 1.2 ± 0.135,p = 0.004)、UC 患者(1.833 ± 0.4.2 vs. 1.444,p = 0.043)、所有 CD 患者(1.59 ± 0.11 vs. 1.29 ± 0.01,p = 0.0001),男性 CD 患者(1.52 ± 0.167 vs. 1.15 ± 0.15,p = 0.016),女性 CD 患者(1.66 ± 0.15 vs. 1.4 ± 0.13,p = 0.0003),女性 UC 患者(1.82 ± 0.32 vs. 1.45 ± 0.31,p = 0.0379),男性 UC 患者略有减少(p = 0.0781)。同样,总体来看,CD 患者的住院率明显降低(0.21 ± 0.04 vs. 0.11 ± 0.03,p = 0.0013),男性 IBD 患者的住院率明显降低(0.175 ± 0.06 vs. 0.05 ± 0.035,p = 0.024), 女性 IBD 患者 (0.21 ± 0.05 vs. 0.11 ± 0.04, p = 0.0072), 男性 CD 患者 (0.18 ± 0.07 vs. 0.06 ± 0.042, p = 0.0436), 以及女性 CD 患者 (0.23 ± 0.06 vs. 0.13 ± 0.04, p = 0.013)。虽然 STABILITY 访谈后粪便钙蛋白、CRP 和血沉的平均值经常降低,但这些数据未达到统计学意义。这些初步研究结果表明,STABILITY 可有效维持 IBD 患者的低疾病活动度或缓解。
{"title":"STABILITY (Symptomatic Review during Biologic Therapy) of Inflammatory Bowel Disease Patients Receiving Infusion Therapy Improves Clinical Outcomes.","authors":"Kelli Morgan, James Morris, Qiang Cai, Phillip Kilgore, Urska Cvek, Marjan Trutschl, Katelynn T Lofton, Meher Sindhoora Mavuram, Prerana Ramesh, Nhi Dao, Ahmed Alhaque, Jonathan Steven Alexander","doi":"10.3390/pathophysiology31030030","DOIUrl":"10.3390/pathophysiology31030030","url":null,"abstract":"&lt;p&gt;&lt;p&gt;Several studies have correlate improved patient outcomes with increased physician-patient contacts, particularly in chronic diseases. Extending this approach to inflammatory bowel disease (IBD) care presents a promising means of improving outcomes. At LSU Health Shreveport (LSUHS), a new approach called \"STABILITY\" (Symptomatic Review during Biologic Therapy) was implemented during infusion therapy visits for IBD patients. These brief 15 min physician-patient interviews aimed to discuss the patients' current IBD-related symptoms and evaluate the need for any changes in their treatment plan. Our goal was to remove a care gap and prevent intensifying symptoms created by missed appointments and loss of contact. To analyze the effectiveness of the STABILITY approach, a retrospective chart review was conducted on 111 IBD patients (18 with ulcerative colitis, 93 with Crohn's disease) seen at LSUHS between 2011 and 2022. Since March 2019, STABILITY has been mandatory for all infusion therapy visits. The data collected included patients' demographics, lab levels for biomarkers (fecal calprotectin, C-reactive protein, and erythrocyte sedimentation rates), hospitalizations, medication changes, and diagnosis dates before and after the implementation of STABILITY. Additionally, voluntary, anonymous infusion patient satisfaction surveys post-STABILITY were used to gather patient responses. In males with IBD, disease severity and hospitalizations were reduced significantly (&lt;i&gt;p&lt;/i&gt; = 0.004 and 0.0234, respectively). In females with IBD, disease severity and hospitalizations were also reduced significantly (&lt;i&gt;p&lt;/i&gt; = 0.0001 and 0.0072, respectively). In patients with UC and CD, there were significant improvements in disease severity (&lt;i&gt;p&lt;/i&gt; = 0.043 and &lt;i&gt;p&lt;/i&gt; = 0.0001, respectively), and CD hospitalizations were also improved (&lt;i&gt;p&lt;/i&gt; = 0.0013). In males and females with UC, disease severity was marginally and significantly reduced (&lt;i&gt;p&lt;/i&gt; = 0.0781 and &lt;i&gt;p&lt;/i&gt; = 0.0379, respectively). In males and females with CD, disease severity was significantly reduced (&lt;i&gt;p&lt;/i&gt; = 0.0161 and 0.0003, respectively), and CD male and female hospitalizations were also reduced significantly (&lt;i&gt;p&lt;/i&gt; = 0.0436 and 0.013). Analyzing of survey responses, we found that the most patients reported improved IBD symptoms (56%), gained understanding of their condition (84%) and were in favor of continuing STABILITY consultations during infusion therapy (93%). To further investigate the impact of STABILITY, we conducted a comparative analysis between IBD patients undergoing STABILITY infusion therapy and LSUHS patients solely on self-injectable biologics. Our paired data analysis showed significant improvements in disease severity in female IBD patients (1.69 ± 0.13 vs. 1.41 ± 0.12, &lt;i&gt;p&lt;/i&gt; = 0.0001) and male IBD patients (1.58 ± 0.16 vs. 1.2 ± 0.135, &lt;i&gt;p&lt;/i&gt; = 0.004), in UC patients (1.833 ± 0.4.2 vs. 1.444, &lt;i&gt;p&lt;/i&gt; = 0.043), in all CD patients (1.59 ± 0.11 vs. 1.29 ± 0","PeriodicalId":19852,"journal":{"name":"Pathophysiology","volume":"31 3","pages":"398-407"},"PeriodicalIF":2.7,"publicationDate":"2024-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11348379/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142073520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Distraction Enterogenesis in Rats: A Novel Approach for the Treatment of Short Bowel Syndrome. 大鼠的牵引性肠发生:治疗短肠综合征的新方法。
IF 2.7 Q2 PATHOLOGY Pub Date : 2024-07-30 DOI: 10.3390/pathophysiology31030029
Collyn O'Quin, Sean D Clayton, Lexus Trosclair, Hannah Meyer, Nhi H Dao, Andrew Minagar, Luke White, Valerie Welch, Giovanni Solitro, Jonathan Steven Alexander, Donald Sorrells

Background: Surgeons often encounter patients with intestinal failure due to inadequate intestinal length ("short bowel syndrome"/SBS). Treatment in these patients remains challenging and the process of physiologic adaptation may take years to complete, which frequently requires parenteral nutrition. We propose a proof-of-concept mechanical bowel elongation approach using a self-expanding prototype of an intestinal expansion sleeve (IES) for use in SBS to accelerate the adaptation process.

Methods: IESs were deployed in the small intestines of Sprague Dawley rats. Mechanical characterization of these prototypes was performed. IES length-tension relationships and post-implant bowel expansion were measured ex vivo. Bowel histology before and after implantation was evaluated.

Results: IES mechanical studies demonstrated decreasing expansive force with elongation. The deployment of IES devices produced an immediate 21 ± 8% increase in bowel length (p < 0.001, n = 11). Mechanical load testing data showed that the IESs expressed maximum expansive forces at 50% compression of the initial pre-contracted length. The small-intestine failure load in the rats was 1.88 ± 21 N. Intestinal histology post deployment of the IES showed significant expansive changes compared to unstretched bowel tissue.

Conclusions: IES devices were scalable to the rat intestinal model in our study. The failure load of the rat small intestine was many times higher than the force exerted by the contraction of the IES. Histology demonstrated preservation of intestinal structure with some mucosal erosion. Future in vivo rat studies on distraction enterogenesis with this IES should help to define this organogenesis phenomenon.

背景:外科医生经常会遇到因肠长度不足而导致肠功能衰竭的病人("短肠综合征"/SBS)。这些患者的治疗仍然具有挑战性,生理适应过程可能需要数年才能完成,而且经常需要肠外营养。我们提出了一种概念验证的机械性肠道伸长方法,使用自膨胀式肠道扩张套筒(IES)原型,用于 SBS,以加速适应过程:方法:在 Sprague Dawley 大鼠的小肠中安装 IES。对这些原型进行了机械表征。在体外测量了 IES 的长度-张力关系和植入后的肠道扩张情况。对植入前后的肠道组织学进行了评估:结果:IES机械研究表明,扩张力随伸长而减小。植入 IES 装置后,肠管长度立即增加了 21 ± 8%(p < 0.001,n = 11)。机械负荷测试数据显示,IES在压缩初始预收缩长度的50%时表现出最大扩张力。与未拉伸的肠道组织相比,IES装置安装后的肠道组织学显示出显著的扩张性变化:结论:在我们的研究中,IES装置可扩展至大鼠肠道模型。结论:在我们的研究中,IES 装置可扩展至大鼠肠道模型。大鼠小肠的失效负荷比 IES 收缩所施加的力高出许多倍。组织学显示肠道结构得以保留,但有部分粘膜受到侵蚀。未来利用这种 IES 进行的大鼠体内牵张肠道生成研究将有助于明确这种器官生成现象。
{"title":"Distraction Enterogenesis in Rats: A Novel Approach for the Treatment of Short Bowel Syndrome.","authors":"Collyn O'Quin, Sean D Clayton, Lexus Trosclair, Hannah Meyer, Nhi H Dao, Andrew Minagar, Luke White, Valerie Welch, Giovanni Solitro, Jonathan Steven Alexander, Donald Sorrells","doi":"10.3390/pathophysiology31030029","DOIUrl":"10.3390/pathophysiology31030029","url":null,"abstract":"<p><strong>Background: </strong>Surgeons often encounter patients with intestinal failure due to inadequate intestinal length (\"short bowel syndrome\"/SBS). Treatment in these patients remains challenging and the process of physiologic adaptation may take years to complete, which frequently requires parenteral nutrition. We propose a proof-of-concept mechanical bowel elongation approach using a self-expanding prototype of an intestinal expansion sleeve (IES) for use in SBS to accelerate the adaptation process.</p><p><strong>Methods: </strong>IESs were deployed in the small intestines of Sprague Dawley rats. Mechanical characterization of these prototypes was performed. IES length-tension relationships and post-implant bowel expansion were measured ex vivo. Bowel histology before and after implantation was evaluated.</p><p><strong>Results: </strong>IES mechanical studies demonstrated decreasing expansive force with elongation. The deployment of IES devices produced an immediate 21 ± 8% increase in bowel length (<i>p</i> < 0.001, <i>n</i> = 11). Mechanical load testing data showed that the IESs expressed maximum expansive forces at 50% compression of the initial pre-contracted length. The small-intestine failure load in the rats was 1.88 ± 21 N. Intestinal histology post deployment of the IES showed significant expansive changes compared to unstretched bowel tissue.</p><p><strong>Conclusions: </strong>IES devices were scalable to the rat intestinal model in our study. The failure load of the rat small intestine was many times higher than the force exerted by the contraction of the IES. Histology demonstrated preservation of intestinal structure with some mucosal erosion. Future in vivo rat studies on distraction enterogenesis with this IES should help to define this organogenesis phenomenon.</p>","PeriodicalId":19852,"journal":{"name":"Pathophysiology","volume":"31 3","pages":"388-397"},"PeriodicalIF":2.7,"publicationDate":"2024-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11348226/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142073519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Autistic Children/Adolescents Have Lower Adherence to the Mediterranean Diet and Higher Salivary IL-6 Concentration: Potential Diet-Inflammation Links? 自闭症儿童/青少年的地中海饮食坚持率较低,唾液 IL-6 浓度较高:饮食与炎症的潜在联系?
IF 2.7 Q2 PATHOLOGY Pub Date : 2024-07-28 DOI: 10.3390/pathophysiology31030028
Milagros Fuentes-Albero, Mayra Alejandra Mafla-España, José Martínez-Raga, Omar Cauli

Background: Autism spectrum disorder (ASD) is one of the most prevalent neurodevelopmental disorders. Many patients with ASD often show behavioral problems at mealtimes, including food selectivity and atypical feeding behaviors. The Mediterranean diet (MD) has a beneficial effect on mental health for the general population across different ages. There is evidence that good adherence to the MD is effective in reducing peripheral inflammatory markers, such as the cytokine interleukin-6 (IL-6). The present study was designed to evaluate adherence to the MD in children with ASD using age- and sex-matched, typically developing individuals (TDs) as a control group and to determine whether differences in adherence to the MD are associated with salivary IL-6 and IL-6 receptor concentration.

Methods: Twenty children and adolescents with ASD (mean age 9.95 ± 0.65 years) and twenty TDs (mean age: 9.85 ± 0.59 years) participated in this study (N = 16 males and N = 4 females in each group). Participants with ASD were enrolled in a psychiatric consultation in Valencia (Spain), and TDs were recruited from two public schools in Valencia. The parents of both ASD and TD groups answered the items in a validated Mediterranean Diet Quality Index for children and adolescents (KIDMED) questionnaire on their children's adherence to the MD.

Results: The mean adherence to MD score was significantly lower in the ASD group (9.10 ± 0.42) (range 6-12) than in the TD group (10.35 ± 0.31) (range 8-12) (p = 0.02, Mann-Whitney U test). There was no statistically significant association between adherence to the MD and age or sex in both groups, but there was a significant correlation between the total KIDMED score and body mass index (BMI) in the ASD group. Regarding the concentration of Il-6 and the Il-6 receptor in saliva samples, there were no significant differences between the two groups; however, linear regression analysis by group revealed significant associations between the adherence to MD score and the concentration of IL-6 and its receptor in saliva in the ASD group (p = 0.003, OR = 0.68, 95% CI 0.007 to -0.02; p = 0.009, OR = -0.64, 95% CI -0.01 to -0.00). In contrast, no significant associations were observed between the adherence to MD score and the concentration of IL-6 and its receptor in saliva in the TD group.

Conclusions: Children and adolescents with ASD showed significantly lower adherence to the MD, which can contribute to nutritional deficits described in ASD, and the role of BMI composition (fat versus lean mass) needs to be further investigated in this group. The concentration of IL-6 and its receptor in saliva is associated with adherence to the MD, suggesting a possible link between IL-6 and diet in ASD. Further studies to clarify the associations between IL-6, psychiatric alterations, and diet in ASD are needed.

背景:自闭症谱系障碍(ASD)是最常见的神经发育障碍之一。许多自闭症谱系障碍患者在进餐时经常出现行为问题,包括食物选择性和非典型进食行为。地中海饮食(Mediterranean diet,MD)对不同年龄段的普通人群的心理健康都有益处。有证据表明,坚持地中海饮食可有效降低外周炎症指标,如细胞因子白细胞介素-6(IL-6)。本研究旨在以年龄和性别匹配的典型发育个体(TDs)为对照组,评估ASD儿童坚持MD的情况,并确定坚持MD的差异是否与唾液IL-6和IL-6受体浓度有关:20名患有自闭症的儿童和青少年(平均年龄为9.95 ± 0.65岁)和20名发育正常的儿童和青少年(平均年龄为9.85 ± 0.59岁)参加了这项研究(每组男性16人,女性4人)。患有自闭症的参与者在巴伦西亚(西班牙)的一家精神科诊所就诊,而患有精神发育迟滞的参与者则是从巴伦西亚的两所公立学校招募的。ASD组和TD组的家长都回答了经过验证的儿童和青少年地中海饮食质量指数(KIDMED)问卷中有关其子女坚持地中海饮食的项目:ASD组坚持地中海饮食的平均得分(9.10 ± 0.42)(6-12分)明显低于TD组(10.35 ± 0.31)(8-12分)(P = 0.02,曼-惠特尼U检验)。在两组中,坚持 MD 与年龄或性别之间没有统计学意义上的显著关联,但在 ASD 组中,KIDMED 总分与体重指数(BMI)之间存在显著相关性。关于唾液样本中Il-6和Il-6受体的浓度,两组之间没有显著差异;但是,按组别进行的线性回归分析表明,ASD组的坚持MD评分与唾液中IL-6及其受体的浓度之间存在显著关联(P = 0.003,OR = 0.68,95% CI 0.007至-0.02;P = 0.009,OR = -0.64,95% CI -0.01至-0.00)。相比之下,在TD组中,坚持MD评分与唾液中IL-6及其受体的浓度之间没有观察到明显的关联:结论:患有 ASD 的儿童和青少年对 MD 的依从性明显较低,这可能是导致 ASD 儿童和青少年营养不良的原因之一。唾液中IL-6及其受体的浓度与坚持MD有关,这表明IL-6与ASD患者的饮食之间可能存在联系。还需要进一步研究来阐明IL-6、精神改变和 ASD 饮食之间的联系。
{"title":"Autistic Children/Adolescents Have Lower Adherence to the Mediterranean Diet and Higher Salivary IL-6 Concentration: Potential Diet-Inflammation Links?","authors":"Milagros Fuentes-Albero, Mayra Alejandra Mafla-España, José Martínez-Raga, Omar Cauli","doi":"10.3390/pathophysiology31030028","DOIUrl":"10.3390/pathophysiology31030028","url":null,"abstract":"<p><strong>Background: </strong>Autism spectrum disorder (ASD) is one of the most prevalent neurodevelopmental disorders. Many patients with ASD often show behavioral problems at mealtimes, including food selectivity and atypical feeding behaviors. The Mediterranean diet (MD) has a beneficial effect on mental health for the general population across different ages. There is evidence that good adherence to the MD is effective in reducing peripheral inflammatory markers, such as the cytokine interleukin-6 (IL-6). The present study was designed to evaluate adherence to the MD in children with ASD using age- and sex-matched, typically developing individuals (TDs) as a control group and to determine whether differences in adherence to the MD are associated with salivary IL-6 and IL-6 receptor concentration.</p><p><strong>Methods: </strong>Twenty children and adolescents with ASD (mean age 9.95 ± 0.65 years) and twenty TDs (mean age: 9.85 ± 0.59 years) participated in this study (N = 16 males and N = 4 females in each group). Participants with ASD were enrolled in a psychiatric consultation in Valencia (Spain), and TDs were recruited from two public schools in Valencia. The parents of both ASD and TD groups answered the items in a validated Mediterranean Diet Quality Index for children and adolescents (KIDMED) questionnaire on their children's adherence to the MD.</p><p><strong>Results: </strong>The mean adherence to MD score was significantly lower in the ASD group (9.10 ± 0.42) (range 6-12) than in the TD group (10.35 ± 0.31) (range 8-12) (<i>p</i> = 0.02, Mann-Whitney U test). There was no statistically significant association between adherence to the MD and age or sex in both groups, but there was a significant correlation between the total KIDMED score and body mass index (BMI) in the ASD group. Regarding the concentration of Il-6 and the Il-6 receptor in saliva samples, there were no significant differences between the two groups; however, linear regression analysis by group revealed significant associations between the adherence to MD score and the concentration of IL-6 and its receptor in saliva in the ASD group (<i>p</i> = 0.003, OR = 0.68, 95% CI 0.007 to -0.02; <i>p</i> = 0.009, OR = -0.64, 95% CI -0.01 to -0.00). In contrast, no significant associations were observed between the adherence to MD score and the concentration of IL-6 and its receptor in saliva in the TD group.</p><p><strong>Conclusions: </strong>Children and adolescents with ASD showed significantly lower adherence to the MD, which can contribute to nutritional deficits described in ASD, and the role of BMI composition (fat versus lean mass) needs to be further investigated in this group. The concentration of IL-6 and its receptor in saliva is associated with adherence to the MD, suggesting a possible link between IL-6 and diet in ASD. Further studies to clarify the associations between IL-6, psychiatric alterations, and diet in ASD are needed.</p>","PeriodicalId":19852,"journal":{"name":"Pathophysiology","volume":"31 3","pages":"376-387"},"PeriodicalIF":2.7,"publicationDate":"2024-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11348102/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142073518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnostic Utility of N-Terminal Pro-B-Type Natriuretic Peptide in Identifying Atrial Fibrillation Post-Cryptogenic Stroke: A Systematic Review and Meta-Analysis. N 端 Pro-B 型钠利尿肽在识别心房颤动隐源性卒中后的诊断效用:系统回顾与元分析》。
IF 2.7 Q2 PATHOLOGY Pub Date : 2024-06-30 DOI: 10.3390/pathophysiology31030024
Jay Patel, Sonu M M Bhaskar

Background: Atrial fibrillation (AF) significantly contributes to acute ischemic stroke, with undetected AF being a common culprit in cryptogenic strokes. N-terminal pro-B-type natriuretic peptide (NT-proBNP), indicative of myocardial stress, has been proposed as a biomarker for AF detection, aiding in the selection of patients for extended cardiac monitoring. However, the diagnostic accuracy of NT-proBNP remains uncertain.

Methods: We conducted a meta-analysis to evaluate the diagnostic accuracy of NT-proBNP in detecting AF among cryptogenic stroke patients. A comprehensive literature search was conducted across PubMed, Embase, and Cochrane databases to identify relevant studies. Studies reporting NT-proBNP levels in stroke patients and data on the proportion of patients with AF above a specified cut-off were included. Meta-analyses were performed using the midas command in STATA.

Results: Seven studies encompassing 2171 patients were included in the analysis, of which five studies contained cohorts with cryptogenic strokes. Among patients with cryptogenic stroke, NT-proBNP demonstrated a diagnostic accuracy of 80% (Area Under the Receiver Operating Curve 0.80 [95% CI 0.76-0.83]), with a sensitivity of 81% (95% CI 0.68-0.89) and a specificity of 68% (95% CI 0.60-0.75).

Conclusion: Our meta-analysis indicates that NT-proBNP exhibits a good-to-very-good diagnostic accuracy for detecting AF in patients with cryptogenic stroke. These findings suggest potential implications for utilizing NT-proBNP in guiding the selection of patients for prolonged cardiac monitoring, thereby aiding in the management of cryptogenic stroke cases.

背景:心房颤动(房颤)是急性缺血性脑卒中的重要诱因,而未被发现的房颤则是隐源性脑卒中的常见罪魁祸首。提示心肌应激的 N 端前 B 型钠尿肽(NT-proBNP)被认为是检测房颤的生物标志物,有助于选择患者进行长期心脏监测。然而,NT-proBNP 的诊断准确性仍不确定:我们进行了一项荟萃分析,以评估 NT-proBNP 在隐源性卒中患者中检测房颤的诊断准确性。我们在 PubMed、Embase 和 Cochrane 数据库中进行了全面的文献检索,以确定相关研究。纳入了报告卒中患者 NT-proBNP 水平的研究以及房颤患者比例超过特定临界值的数据。使用 STATA 中的 midas 命令进行 Meta 分析:共有 7 项研究纳入分析,涵盖 2171 名患者,其中 5 项研究包含隐源性脑卒中队列。在隐源性卒中患者中,NT-proBNP 的诊断准确率为 80%(接收者工作曲线下面积为 0.80 [95% CI 0.76-0.83]),敏感性为 81%(95% CI 0.68-0.89),特异性为 68%(95% CI 0.60-0.75):我们的荟萃分析表明,NT-proBNP 对隐源性卒中患者房颤的检测具有良好至非常好的诊断准确性。这些研究结果表明,利用 NT-proBNP 指导选择患者进行长期心脏监测具有潜在的意义,从而有助于隐源性卒中病例的管理。
{"title":"Diagnostic Utility of N-Terminal Pro-B-Type Natriuretic Peptide in Identifying Atrial Fibrillation Post-Cryptogenic Stroke: A Systematic Review and Meta-Analysis.","authors":"Jay Patel, Sonu M M Bhaskar","doi":"10.3390/pathophysiology31030024","DOIUrl":"10.3390/pathophysiology31030024","url":null,"abstract":"<p><strong>Background: </strong>Atrial fibrillation (AF) significantly contributes to acute ischemic stroke, with undetected AF being a common culprit in cryptogenic strokes. N-terminal pro-B-type natriuretic peptide (NT-proBNP), indicative of myocardial stress, has been proposed as a biomarker for AF detection, aiding in the selection of patients for extended cardiac monitoring. However, the diagnostic accuracy of NT-proBNP remains uncertain.</p><p><strong>Methods: </strong>We conducted a meta-analysis to evaluate the diagnostic accuracy of NT-proBNP in detecting AF among cryptogenic stroke patients. A comprehensive literature search was conducted across PubMed, Embase, and Cochrane databases to identify relevant studies. Studies reporting NT-proBNP levels in stroke patients and data on the proportion of patients with AF above a specified cut-off were included. Meta-analyses were performed using the midas command in STATA.</p><p><strong>Results: </strong>Seven studies encompassing 2171 patients were included in the analysis, of which five studies contained cohorts with cryptogenic strokes. Among patients with cryptogenic stroke, NT-proBNP demonstrated a diagnostic accuracy of 80% (Area Under the Receiver Operating Curve 0.80 [95% CI 0.76-0.83]), with a sensitivity of 81% (95% CI 0.68-0.89) and a specificity of 68% (95% CI 0.60-0.75).</p><p><strong>Conclusion: </strong>Our meta-analysis indicates that NT-proBNP exhibits a good-to-very-good diagnostic accuracy for detecting AF in patients with cryptogenic stroke. These findings suggest potential implications for utilizing NT-proBNP in guiding the selection of patients for prolonged cardiac monitoring, thereby aiding in the management of cryptogenic stroke cases.</p>","PeriodicalId":19852,"journal":{"name":"Pathophysiology","volume":"31 3","pages":"331-349"},"PeriodicalIF":2.7,"publicationDate":"2024-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11270372/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141760217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Gut Microbiome Interactions with Oxidative Stress: Mechanisms and Consequences for Health. 肠道微生物组与氧化应激的相互作用:健康的机理和后果。
IF 2.7 Q2 PATHOLOGY Pub Date : 2024-06-21 DOI: 10.3390/pathophysiology31030023
Natalya Semenova, Nadezhda Garashchenko, Sergey Kolesnikov, Marina Darenskaya, Liubov Kolesnikova

Understanding how gut flora interacts with oxidative stress has been the subject of significant research in recent years. There is much evidence demonstrating the existence of the microbiome-oxidative stress interaction. However, the biochemical basis of this interaction is still unclear. In this narrative review, possible pathways of the gut microbiota and oxidative stress interaction are presented, among which genetic underpinnings play an important role. Trimethylamine-N-oxide, mitochondria, short-chain fatty acids, and melatonin also appear to play roles. Moreover, the relationship between oxidative stress and the gut microbiome in obesity, metabolic syndrome, chronic ethanol consumption, dietary supplements, and medications is considered. An investigation of the correlation between bacterial community features and OS parameter changes under normal and pathological conditions might provide information for the determination of new research methods. Furthermore, such research could contribute to establishing a foundation for determining the linkers in the microbiome-OS association.

了解肠道菌群如何与氧化应激相互作用是近年来的重要研究课题。许多证据表明微生物群与氧化应激之间存在相互作用。然而,这种相互作用的生化基础仍不清楚。在这篇叙述性综述中,介绍了肠道微生物群与氧化应激相互作用的可能途径,其中遗传基础起着重要作用。三甲胺-N-氧化物、线粒体、短链脂肪酸和褪黑激素似乎也发挥了作用。此外,还考虑了肥胖、代谢综合征、慢性乙醇消费、膳食补充剂和药物中氧化应激与肠道微生物组之间的关系。对正常和病理情况下细菌群落特征与操作系统参数变化之间的相关性进行调查,可为确定新的研究方法提供信息。此外,此类研究还有助于为确定微生物群与操作系统之间的联系奠定基础。
{"title":"Gut Microbiome Interactions with Oxidative Stress: Mechanisms and Consequences for Health.","authors":"Natalya Semenova, Nadezhda Garashchenko, Sergey Kolesnikov, Marina Darenskaya, Liubov Kolesnikova","doi":"10.3390/pathophysiology31030023","DOIUrl":"10.3390/pathophysiology31030023","url":null,"abstract":"<p><p>Understanding how gut flora interacts with oxidative stress has been the subject of significant research in recent years. There is much evidence demonstrating the existence of the microbiome-oxidative stress interaction. However, the biochemical basis of this interaction is still unclear. In this narrative review, possible pathways of the gut microbiota and oxidative stress interaction are presented, among which genetic underpinnings play an important role. Trimethylamine-N-oxide, mitochondria, short-chain fatty acids, and melatonin also appear to play roles. Moreover, the relationship between oxidative stress and the gut microbiome in obesity, metabolic syndrome, chronic ethanol consumption, dietary supplements, and medications is considered. An investigation of the correlation between bacterial community features and OS parameter changes under normal and pathological conditions might provide information for the determination of new research methods. Furthermore, such research could contribute to establishing a foundation for determining the linkers in the microbiome-OS association.</p>","PeriodicalId":19852,"journal":{"name":"Pathophysiology","volume":"31 3","pages":"309-330"},"PeriodicalIF":2.7,"publicationDate":"2024-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11270257/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141760218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bronchial Asthma and COVID-19: Etiology, Pathological Triggers, and Therapeutic Considerations. 支气管哮喘与 COVID-19:病因、病理诱因和治疗考虑。
IF 2.7 Q2 PATHOLOGY Pub Date : 2024-05-27 DOI: 10.3390/pathophysiology31020020
Anna Starshinova, Anastasia Borozinets, Anastasia Kulpina, Vitaliy Sereda, Artem Rubinstein, Igor Kudryavtsev, Dmitry Kudlay

Bronchial asthma (BA) continues to be a difficult disease to diagnose. Various factors have been described in the development of BA, but to date, there is no clear evidence for the etiology of this chronic disease. The emergence of COVID-19 has contributed to the pandemic course of asthma and immunologic features. However, there are no unambiguous data on asthma on the background and after COVID-19. There is correlation between various trigger factors that provoke the development of bronchial asthma. It is now obvious that the SARS-CoV-2 virus is one of the provoking factors. COVID-19 has affected the course of asthma. Currently, there is no clear understanding of whether asthma progresses during or after COVID-19 infection. According to the results of some studies, a significant difference was identified between the development of asthma in people after COVID-19. Mild asthma and moderate asthma do not increase the severity of COVID-19 infection. Nevertheless, oral steroid treatment and hospitalization for severe BA were associated with higher COVID-19 severity. The influence of SARS-CoV-2 infection is one of the protective factors. It causes the development of severe bronchial asthma. The accumulated experience with omalizumab in patients with severe asthma during COVID-19, who received omalizumab during the pandemic, has strongly suggested that continued treatment with omalizumab is safe and may help prevent the severe course of COVID-19. Targeted therapy for asthma with the use of omalizumab may also help to reduce severe asthma associated with COVID-19. However, further studies are needed to prove the effect of omalizumab. Data analysis should persist, based on the results of the course of asthma after COVID-19 with varying degrees of severity.

支气管哮喘(BA)仍然是一种难以诊断的疾病。人们描述了支气管哮喘发病的各种因素,但迄今为止,还没有明确的证据表明这种慢性疾病的病因。COVID-19 的出现促成了哮喘的流行过程和免疫学特征。然而,目前还没有关于 COVID-19 背景和之后的哮喘的明确数据。引发支气管哮喘的各种诱发因素之间存在相关性。现在很明显,SARS-CoV-2 病毒是诱发因素之一。COVID-19 影响了哮喘的病程。目前,人们对 COVID-19 感染期间或感染后哮喘是否发展尚无明确认识。一些研究结果表明,COVID-19 感染后,人们的哮喘发展有显著差异。轻度哮喘和中度哮喘不会增加 COVID-19 感染的严重程度。然而,口服类固醇治疗和因严重 BA 而住院治疗与 COVID-19 的严重程度较高有关。SARS-CoV-2 感染的影响是保护因素之一。它导致严重支气管哮喘的发生。在 COVID-19 大流行期间接受奥马珠单抗治疗的重症哮喘患者积累的经验有力地表明,继续使用奥马珠单抗治疗是安全的,可能有助于预防 COVID-19 的严重病程。使用奥马珠单抗对哮喘进行靶向治疗也可能有助于减少与 COVID-19 相关的严重哮喘。然而,要证明奥马珠单抗的效果,还需要进一步的研究。应根据 COVID-19 后不同严重程度哮喘的病程结果,坚持进行数据分析。
{"title":"Bronchial Asthma and COVID-19: Etiology, Pathological Triggers, and Therapeutic Considerations.","authors":"Anna Starshinova, Anastasia Borozinets, Anastasia Kulpina, Vitaliy Sereda, Artem Rubinstein, Igor Kudryavtsev, Dmitry Kudlay","doi":"10.3390/pathophysiology31020020","DOIUrl":"10.3390/pathophysiology31020020","url":null,"abstract":"<p><p>Bronchial asthma (BA) continues to be a difficult disease to diagnose. Various factors have been described in the development of BA, but to date, there is no clear evidence for the etiology of this chronic disease. The emergence of COVID-19 has contributed to the pandemic course of asthma and immunologic features. However, there are no unambiguous data on asthma on the background and after COVID-19. There is correlation between various trigger factors that provoke the development of bronchial asthma. It is now obvious that the SARS-CoV-2 virus is one of the provoking factors. COVID-19 has affected the course of asthma. Currently, there is no clear understanding of whether asthma progresses during or after COVID-19 infection. According to the results of some studies, a significant difference was identified between the development of asthma in people after COVID-19. Mild asthma and moderate asthma do not increase the severity of COVID-19 infection. Nevertheless, oral steroid treatment and hospitalization for severe BA were associated with higher COVID-19 severity. The influence of SARS-CoV-2 infection is one of the protective factors. It causes the development of severe bronchial asthma. The accumulated experience with omalizumab in patients with severe asthma during COVID-19, who received omalizumab during the pandemic, has strongly suggested that continued treatment with omalizumab is safe and may help prevent the severe course of COVID-19. Targeted therapy for asthma with the use of omalizumab may also help to reduce severe asthma associated with COVID-19. However, further studies are needed to prove the effect of omalizumab. Data analysis should persist, based on the results of the course of asthma after COVID-19 with varying degrees of severity.</p>","PeriodicalId":19852,"journal":{"name":"Pathophysiology","volume":"31 2","pages":"269-287"},"PeriodicalIF":2.7,"publicationDate":"2024-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11206645/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141451130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Depth of SCUBA Diving Affects Cardiac Autonomic Nervous System. 水肺潜水深度对心脏自主神经系统的影响
Q2 PATHOLOGY Pub Date : 2024-03-29 DOI: 10.3390/pathophysiology31020014
Marina Vulić, Branislav Milovanovic, Ante Obad, Duška Glavaš, Igor Glavicic, Damir Zubac, Maja Valic, Zoran Valic

The present study investigated the influence of SCUBA dives with compressed air at depths of 10 and 20 m on ECG-derived HRV parameters in apparently healthy individuals. We hypothesized that cardiac sympathetic activity (measured by HRV parameters) adapts proportionally to diving depth, and that both time- and frequency-domain parameters are sensitive enough to track changes in cardiac ANS function during diving activities and subsequently during the recovery period. Eleven healthy middle-aged recreational divers (nine men and two women, age 43 ± 8, all nonsmokers) volunteered to participate in the present study. The participants (all open-circuit divers) were equipped with dry suits and ECG Holter devices and were later randomly assigned to dive pairs and depths (10 m vs. 20 m), and each participant served as his or her own control. No interaction effects (diving depth x time epoch) were found for the most commonly used HRV markers. More precisely, in response to two different diving protocols, a significant post hoc effect of time was observed for HR and SDNN, as these parameters transiently decreased during the dives and returned to baseline after ascent (p < 0.001). The ULF, VLF (p < 0.003), TP, and LF parameters decreased significantly during the dives, while HF significantly increased (p < 0.003). SCUBA diving apparently challenges the cardiac ANS, even in healthy individuals. The observed changes reveal possible underwater methods of influencing the parasympathetic activity of the heart depending on the depth of the dive. These results identify autonomic nervous system markers to track the cardiovascular risk related to diving and point to the possibility of tracking cardiovascular system benefits during underwater activities in selected patients.

本研究调查了在 10 米和 20 米深处使用压缩空气进行 SCUBA 潜水对表面上健康的人心电图心率变异参数的影响。我们假设心脏交感神经活动(通过心率变异参数测量)与潜水深度成比例地适应,并且时域和频域参数都足够灵敏,可以跟踪潜水活动期间以及随后恢复期间心脏自律神经系统功能的变化。11 名健康的中年休闲潜水员(9 男 2 女,年龄 43 ± 8 岁,均不吸烟)自愿参加了本研究。参与者(均为开圈潜水员)均配备了干式潜水服和心电图 Holter 设备,随后被随机分配到不同的潜水对和深度(10 米与 20 米),每位参与者作为自己的对照组。对于最常用的心率变异标记,没有发现交互效应(潜水深度 x 时间历时)。更确切地说,针对两种不同的潜水方案,观察到时间对心率和 SDNN 有显著的事后效应,因为这些参数在潜水过程中短暂下降,并在上升后恢复到基线(p < 0.001)。在潜水过程中,ULF、VLF(p < 0.003)、TP 和 LF 参数显著下降,而 HF 则显著上升(p < 0.003)。水肺潜水显然对心脏自律神经系统提出了挑战,即使是健康人也不例外。观察到的变化揭示了根据潜水深度影响心脏副交感神经活动的可能水下方法。这些结果确定了自律神经系统标记,可用于跟踪与潜水有关的心血管风险,并指出在选定的患者进行水下活动期间跟踪心血管系统益处的可能性。
{"title":"Depth of SCUBA Diving Affects Cardiac Autonomic Nervous System.","authors":"Marina Vulić, Branislav Milovanovic, Ante Obad, Duška Glavaš, Igor Glavicic, Damir Zubac, Maja Valic, Zoran Valic","doi":"10.3390/pathophysiology31020014","DOIUrl":"https://doi.org/10.3390/pathophysiology31020014","url":null,"abstract":"<p><p>The present study investigated the influence of SCUBA dives with compressed air at depths of 10 and 20 m on ECG-derived HRV parameters in apparently healthy individuals. We hypothesized that cardiac sympathetic activity (measured by HRV parameters) adapts proportionally to diving depth, and that both time- and frequency-domain parameters are sensitive enough to track changes in cardiac ANS function during diving activities and subsequently during the recovery period. Eleven healthy middle-aged recreational divers (nine men and two women, age 43 ± 8, all nonsmokers) volunteered to participate in the present study. The participants (all open-circuit divers) were equipped with dry suits and ECG Holter devices and were later randomly assigned to dive pairs and depths (10 m vs. 20 m), and each participant served as his or her own control. No interaction effects (diving depth x time epoch) were found for the most commonly used HRV markers. More precisely, in response to two different diving protocols, a significant post hoc effect of time was observed for HR and SDNN, as these parameters transiently decreased during the dives and returned to baseline after ascent (<i>p</i> < 0.001). The ULF, VLF (<i>p</i> < 0.003), TP, and LF parameters decreased significantly during the dives, while HF significantly increased (<i>p</i> < 0.003). SCUBA diving apparently challenges the cardiac ANS, even in healthy individuals. The observed changes reveal possible underwater methods of influencing the parasympathetic activity of the heart depending on the depth of the dive. These results identify autonomic nervous system markers to track the cardiovascular risk related to diving and point to the possibility of tracking cardiovascular system benefits during underwater activities in selected patients.</p>","PeriodicalId":19852,"journal":{"name":"Pathophysiology","volume":"31 2","pages":"183-189"},"PeriodicalIF":0.0,"publicationDate":"2024-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11036274/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140852330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Inhibition of miR-33a-5p in Macrophage-like Cells In Vitro Promotes apoAI-Mediated Cholesterol Efflux. 抑制体外巨噬细胞样细胞中的 miR-33a-5p 可促进载脂蛋白 A 诱导的胆固醇外流。
Q2 PATHOLOGY Pub Date : 2024-02-28 DOI: 10.3390/pathophysiology31010009
Olanrewaju Oladosu, Emma Chin, Christian Barksdale, Rhonda R Powell, Terri Bruce, Alexis Stamatikos

Atherosclerosis is caused by cholesterol accumulation within arteries. The intima is where atherosclerotic plaque accumulates and where lipid-laden foam cells reside. Intimal foam cells comprise of both monocyte-derived macrophages and macrophage-like cells (MLC) of vascular smooth muscle cell (VSMC) origin. Foam cells can remove cholesterol via apoAI-mediated cholesterol efflux and this process is regulated by the transporter ABCA1. The microRNA miR-33a-5p is thought to be atherogenic via silencing ABCA1 which promotes cholesterol retention and data has shown inhibiting miR-33a-5p in macrophages may be atheroprotective via enhancing apoAI-mediated cholesterol efflux. However, it is not entirely elucidated whether precisely inhibiting miR-33a-5p in MLC also increases ABCA1-dependent cholesterol efflux. Therefore, the purpose of this work is to test the hypothesis that inhibition of miR-33a-5p in cultured MLC enhances apoAI-mediated cholesterol efflux. In our study, we utilized the VSMC line MOVAS cells in our experiments, and cholesterol-loaded MOVAS cells to convert this cell line into MLC. Inhibition of miR-33a-5p was accomplished by transducing cells with a lentivirus that expresses an antagomiR directed at miR-33a-5p. Expression of miR-33a-5p was analyzed by qRT-PCR, ABCA1 protein expression was assessed via immunoblotting, and apoAI-mediated cholesterol efflux was measured using cholesterol efflux assays. In our results, we demonstrated that lentiviral vector-mediated knockdown of miR-33a-5p resulted in decreasing expression of this microRNA in cultured MLC. Moreover, reduction of miR-33a-5p in cultured MLC resulted in de-repression of ABCA1 expression, which caused ABCA1 protein upregulation in cultured MLC. Additionally, this increase in ABCA1 protein expression resulted in enhancing ABCA1-dependent cholesterol efflux through increasing apoAI-mediated cholesterol efflux in cultured MLC. From these findings, we conclude that inhibiting miR-33a-5p in MLC may protect against atherosclerosis by promoting ABCA1-dependent cholesterol efflux.

动脉粥样硬化是由胆固醇在动脉内积聚造成的。动脉内膜是动脉粥样硬化斑块的聚集地,也是脂质泡沫细胞的栖息地。内膜泡沫细胞由来源于单核细胞的巨噬细胞和来源于血管平滑肌细胞(VSMC)的巨噬细胞样细胞(MLC)组成。泡沫细胞可通过载脂蛋白AI介导的胆固醇外流清除胆固醇,这一过程受转运体ABCA1的调节。有数据显示,抑制巨噬细胞中的 miR-33a-5p 可通过增强 apoAI 介导的胆固醇外流起到保护动脉粥样硬化的作用。然而,精确抑制 MLC 中的 miR-33a-5p 是否也会增加 ABCA1 依赖的胆固醇外流,目前还没有完全阐明。因此,本研究的目的是检验在培养的 MLC 中抑制 miR-33a-5p 是否会增强 apoAI 介导的胆固醇外流的假设。在我们的研究中,我们利用 VSMC 细胞系 MOVAS 细胞进行实验,并利用胆固醇负载的 MOVAS 细胞将该细胞系转化为 MLC。抑制 miR-33a-5p 的方法是用表达针对 miR-33a-5p 的抗噬菌体的慢病毒转导细胞。miR-33a-5p 的表达通过 qRT-PCR 进行分析,ABCA1 蛋白的表达通过免疫印迹进行评估,apoAI 介导的胆固醇外流通过胆固醇外流测定进行测量。我们的研究结果表明,慢病毒载体介导的 miR-33a-5p 基因敲除导致培养的 MLC 中该 microRNA 的表达下降。此外,培养的 MLC 中 miR-33a-5p 的减少导致 ABCA1 表达的去抑制,从而引起培养的 MLC 中 ABCA1 蛋白的上调。此外,ABCA1 蛋白表达的增加导致培养 MLC 中载脂蛋白介导的胆固醇外流增加,从而增强了 ABCA1 依赖性胆固醇外流。根据这些发现,我们得出结论:抑制 MLC 中的 miR-33a-5p 可促进 ABCA1 依赖性胆固醇外流,从而预防动脉粥样硬化。
{"title":"Inhibition of miR-33a-5p in Macrophage-like Cells In Vitro Promotes apoAI-Mediated Cholesterol Efflux.","authors":"Olanrewaju Oladosu, Emma Chin, Christian Barksdale, Rhonda R Powell, Terri Bruce, Alexis Stamatikos","doi":"10.3390/pathophysiology31010009","DOIUrl":"10.3390/pathophysiology31010009","url":null,"abstract":"<p><p>Atherosclerosis is caused by cholesterol accumulation within arteries. The intima is where atherosclerotic plaque accumulates and where lipid-laden foam cells reside. Intimal foam cells comprise of both monocyte-derived macrophages and macrophage-like cells (MLC) of vascular smooth muscle cell (VSMC) origin. Foam cells can remove cholesterol via apoAI-mediated cholesterol efflux and this process is regulated by the transporter ABCA1. The microRNA miR-33a-5p is thought to be atherogenic via silencing ABCA1 which promotes cholesterol retention and data has shown inhibiting miR-33a-5p in macrophages may be atheroprotective via enhancing apoAI-mediated cholesterol efflux. However, it is not entirely elucidated whether precisely inhibiting miR-33a-5p in MLC also increases ABCA1-dependent cholesterol efflux. Therefore, the purpose of this work is to test the hypothesis that inhibition of miR-33a-5p in cultured MLC enhances apoAI-mediated cholesterol efflux. In our study, we utilized the VSMC line MOVAS cells in our experiments, and cholesterol-loaded MOVAS cells to convert this cell line into MLC. Inhibition of miR-33a-5p was accomplished by transducing cells with a lentivirus that expresses an antagomiR directed at miR-33a-5p. Expression of miR-33a-5p was analyzed by qRT-PCR, ABCA1 protein expression was assessed via immunoblotting, and apoAI-mediated cholesterol efflux was measured using cholesterol efflux assays. In our results, we demonstrated that lentiviral vector-mediated knockdown of miR-33a-5p resulted in decreasing expression of this microRNA in cultured MLC. Moreover, reduction of miR-33a-5p in cultured MLC resulted in de-repression of ABCA1 expression, which caused ABCA1 protein upregulation in cultured MLC. Additionally, this increase in ABCA1 protein expression resulted in enhancing ABCA1-dependent cholesterol efflux through increasing apoAI-mediated cholesterol efflux in cultured MLC. From these findings, we conclude that inhibiting miR-33a-5p in MLC may protect against atherosclerosis by promoting ABCA1-dependent cholesterol efflux.</p>","PeriodicalId":19852,"journal":{"name":"Pathophysiology","volume":"31 1","pages":"117-126"},"PeriodicalIF":0.0,"publicationDate":"2024-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10976131/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140294231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Pathophysiology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1